PSY17 Cost-Utility Analysis of Immune Tolerance Induction (ITI) Therapy Versus On-Demand Treatment With Recombinant FVII (rFVIIa) for Hemophilia A With High Titer Inhibitors in Iran

Nov 1, 2012, 00:00
10.1016/j.jval.2012.08.461
https://www.valueinhealthjournal.com/article/S1098-3015(12)02174-2/fulltext
Title : PSY17 Cost-Utility Analysis of Immune Tolerance Induction (ITI) Therapy Versus On-Demand Treatment With Recombinant FVII (rFVIIa) for Hemophilia A With High Titer Inhibitors in Iran
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)02174-2&doi=10.1016/j.jval.2012.08.461
First page : A680
Section Title : Systemic Disorders/Conditions
Open access? : No
Section Order : 1989
Categories :
Tags :
Regions :
ViH Article Tags :